---
title: "Top 10 美股跌幅（2月23日）"
description: "诺和诺德公司 (NVO) 跌 16.43%，成交额 39.4 亿美元，年内累计跌 22.1%。 GRAIL(GRAL) 跌 14.3%，成交额 2.4 亿美元，年内累计跌 49.7%。 IBM(IBM) 跌 13.15%，成交额 44.8 亿美元，年内累计跌 24.2%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276650718.md"
published_at: "2026-02-23T22:01:01.000Z"
---

# Top 10 美股跌幅（2月23日）

> 诺和诺德公司 (NVO) 跌 16.43%，成交额 39.4 亿美元，年内累计跌 22.1%。 GRAIL(GRAL) 跌 14.3%，成交额 2.4 亿美元，年内累计跌 49.7%。 IBM(IBM) 跌 13.15%，成交额 44.8 亿美元，年内累计跌 24.2%。

纳斯达克综合指数跌 1.13%，年内累计跌 2.6%；标普 500 指数跌 1.04%，年内累计跌 0.1%；道琼斯指数跌 1.66%，年内累计涨 1.5%。

诺和诺德公司 (NVO) 跌 16.43%，成交额 39.4 亿美元，年内累计跌 22.1%。

GRAIL(GRAL) 跌 14.3%，成交额 2.4 亿美元，年内累计跌 49.7%。

IBM(IBM) 跌 13.15%，成交额 44.8 亿美元，年内累计跌 24.2%。

### Related Stocks

- [NVO.US - 诺和诺德公司](https://longbridge.com/zh-CN/quote/NVO.US.md)
- [GRAL.US - GRAIL](https://longbridge.com/zh-CN/quote/GRAL.US.md)
- [IBM.US - IBM](https://longbridge.com/zh-CN/quote/IBM.US.md)
- [RNG.US - Ringcentral](https://longbridge.com/zh-CN/quote/RNG.US.md)
- [STEP.US - Stepstone](https://longbridge.com/zh-CN/quote/STEP.US.md)
- [SLM.US - SLM](https://longbridge.com/zh-CN/quote/SLM.US.md)
- [LMND.US - Lemonade](https://longbridge.com/zh-CN/quote/LMND.US.md)
- [TENB.US - Tenable](https://longbridge.com/zh-CN/quote/TENB.US.md)
- [COMP.US - Compass](https://longbridge.com/zh-CN/quote/COMP.US.md)
- [MDB.US - MongoDB](https://longbridge.com/zh-CN/quote/MDB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| IBM Stock Is Trending After Crating 13% And Claude-Maker Anthropic Is The Reason Why: Here's What Happened | IBM shares fell 13% after Anthropic's Claude Code AI tool raised concerns about potential disruption to IBM's legacy mai | [Link](https://longbridge.com/zh-CN/news/276674951.md) |
| Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | [Link](https://longbridge.com/zh-CN/news/276440991.md) |
| Key facts: Novo Nordisk Faces Challenges with CagriSema; $35B M&A Plans | J.P. Morgan analysts raised concerns about CagriSema's underperformance, which may affect demand and long-term sales for | [Link](https://longbridge.com/zh-CN/news/276670594.md) |
| Novo Nordisk's CagriSema Fails to Meet Primary Endpoint in Phase 3 Obesity Trial | Novo Nordisk's CagriSema Fails to Meet Primary Endpoint in Phase 3 Obesity Trial | [Link](https://longbridge.com/zh-CN/news/276591721.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/zh-CN/news/276447697.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。